Abstract Body

Background

Serious non-AIDS events (SNAEs) are steadily increasing, in particular cardiovascular disease (CVD) and death. People with HIV (PWH) on antiretroviral therapy (ART) develop SNAEs earlier and with less traditional risk factors compared to their counterparts without HIV, despite viral suppression. Risk models using cardiovascular biomarkers showed that improved ART adherence beyond what is needed for viral suppression reduced SNAE risk. We sought to determine the time-varying effect of ART adherence on the incidence of the clinical SNAE outcomes of CVD and death.

Methods

We performed a secondary analysis of the prospective observational ACTG A5001 and A5322 studies. The baseline was defined as the time at first viral suppression to <200 copies/mL after treatment initiation. Adherence to ART was assessed using the periodically administered ACTG self-report questionnaire, with percentage adherence calculated as the proportion of prescribed doses taken over the preceding four days. Data were primarily analyzed using inverse probability of censoring weights (IPCW) modelling, with sensitivity analyses conducted using generalized estimating equations (GEE).

Results

Among 2,932 participants followed for a median of 4.3 years, 260 SNAEs occurred, comprising 125 deaths and 135 cardiovascular events. Most were men (82.2%) with a median age of 39 years (IQR 32 – 47). For the duration of follow-up, the median viral load remained suppressed at <50 copies/mL (IQR <50 – 67) over an average of 3.1 sampling timepoints per year (IQR 2.6 – 3.6), with 95.8% remaining <200 copies/mL. The mean self-reported ART adherence was 97.1% (95% CI 97.0 – 97.2) captured over a median of 2.2 reports per year (IQR 1.8 – 3.0). Higher ART adherence was significantly associated with a reduced risk of first SNAE: each 10% increase in adherence decreased SNAE risk by 9% (adjusted hazard ratio 0.991, 95% confidence interval 0.982–0.999; Figure 1). Increased age and higher viral load were significantly associated with greater SNAE risk, while former smokers or those who never smoked had significantly lower risk compared to current smokers. Only adherence and age remained significant with the GEE sensitivity analyses for both first SNAE and all SNAEs during follow-up.

Conclusions

Higher ART adherence reduces SNAE risk even in virally suppressed PWH. Globally, ART adherence remains challenging, and enhanced efforts are needed for continued adherence support despite achieving viral suppression to improve long-term health outcomes.

Table or Figure